Continuing Medical Education for Pharmacists | Earn Free CME Credits

Education

Search

Saved Activities

0 Activities

0 Activities

Filter Content

Results 1 - 59 of 59

animation-263x149

Considerations to Encourage Patient Engagement and Shared Decision-making

Cognitive Impairment Associated With Schizophrenia

9235-0005_thumb

Recent Developments in Immune Therapies for Multiple Sclerosis

9235-mod4-263x149

The Connection Between Viruses and Other Factors Contributing to the Development of MS

Comorbidities and Selection of DMTs

Management of Breakthrough Disease Activity

COVID-19 Associated ARDS

COVID-19 and Comorbid ILD

Minimizing Neurodegenerative Damage in Patients with MS

Recognizing Progressive Disease: A Challenge in the MS Clinic

DMT Treatment Review

IPF Animated Video Series: Micro-learning focusing on the soft skills

Palliative Care for mRRC

Salvage Therapies for Metastatic Renal Cell Carcinoma

Is There Still a Role For Cytoreductive Nephrectomy

Management of Rare RCC Histologies

Contemporary Topics in RCC: Tumor Board

End of Life in IPF

Comprehensive Care of the ILD Patient–Focus on Symptoms

Developing an Action Plan

Diagnosis of Interstitial Lung Disease

Applying Principles of Pain Management

Patient Case: Osteoarthritis (OA) of the Knee

Patient Case: Lower Back Pain

Personalized Medicine for Improving Asthma Care: An Animated Video Series

Discussions with Patients to Optimize Asthma Control

9916-0004_treatment

Who Should be Targeted For Treatment With Biologic Therapy?

9916-0003_endotypes

Endotypes and Phenotypes in Asthma

Mechanisms of Action of Biologic Therapies for Severe Asthma

Approved Medications for the Treatment of Severe Asthma

9907-0006_shared

Engage Your Patients in Shared Decision-Making

9907-0005_cardio

Is It IPF or Cardiovascular Disease?

Interstitial Pneumonia with Autoimmune Features

9907-0003_pf-ild

How to Identify Progressive Fibrosing ILD

When Is It a Connective Tissue Disease?

9907-0001_guidelines

How to Use IPF Guidelines to Make a Diagnosis

Biosimilars: Applying the Science to Hematology/Oncology Practice

Considering Biosimilars in Patients Failing their Initial Biologic

When to Switch? Biologically Experienced Patients with Spondyloarthritis

Innovator or Biosimilar for a Patient with Rheumatoid Arthritis

IL-gastro-case3

Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?

IL-gastro-case2

Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic

IL-gastro-case1

Innovator or Biosimilar for a Patient with Ulcerative Colitis?

Switching Between Biologics: Is a Biosimilar an Option?

When to Switch? Biologically Experienced Psoriasis Patients

Innovator or Biosimilar for a Patient with Psoriasis

Interchangeability and Pharmacy-Level Substitution

FDA Criteria: Biosimilar Approval, Manufacturing, & Naming

What is the Difference Between a Biosimilar and a Generic?

What is a Biologic?

Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics

Are You Ready to Use Biosimilars in Your Practice?

Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?

Pharmacovigilance and Biosimilars: Any Special Considerations?

Interchangeability and Biosimilars: What will this Mean for Clinical Practice?

Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?

Biosimilars: As Safe and Effective as the Reference Product?

Drift and the Manufacturing of Biologics: What is it and Does it Matter?

Biosimilars in Clinical Practice: Interchangeability and Extrapolation